Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5089Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | De Caterina R | - |
| dc.date | 2011 | - |
| dc.date.accessioned | 2013-05-30T12:14:46Z | - |
| dc.date.available | 2013-05-30T12:14:46Z | - |
| dc.date.issued | 2013-05-30 | - |
| dc.identifier | http://www.dovepress.com/clinical-experience-with-apixaban-in-atrial-fibrillation-implications--a7889 | - |
| dc.identifier | http://www.doaj.org/doaj?func=openurl&genre=article&issn=11798475&date=2011&volume=2011&issue=default&spage=83 | - |
| dc.identifier.uri | http://koha.mediu.edu.my:8181/jspui/handle/123456789/5089 | - |
| dc.description | Raffaele De CaterinaInstitute of Cardiology and Center of Excellence on Aging, G d’Annunzio University, Chieti, G Monasterio Foundation, Pisa, ItalyAbstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the risk of stroke and thromboembolism. Prevention of stroke and thromboembolism is therefore an important part of the management of atrial fibrillation. Guidelines until now have recommended that patients with atrial fibrillation receive some form of antithrombotic therapy, ie, a vitamin K antagonist or aspirin, with a preference for anticoagulants in most cases. However, current treatments are suboptimal, and despite the recommendations, many patients do not receive adequate thromboprophylaxis, because they are considered, for various reasons, “unsuitable” to receive a vitamin K antagonist. In this patient population, apixaban, a new oral anticoagulant inhibiting activated coagulation factor X, administered in fixed doses and without anticoagulation monitoring, has undergone testing against aspirin in the recently published AVERROES trial. This paper addresses the strengths and limitations of this trial and the practical relevance of the new clinical information it provides.Keywords: atrial fibrillation, apixaban, thromboprophylaxis | - |
| dc.language | eng | - |
| dc.publisher | Dove Press | - |
| dc.source | Research Reports in Clinical Cardiology | - |
| dc.title | Clinical experience with apixaban in atrial fibrillation: implications of AVERROES | - |
| Appears in Collections: | Health Sciences | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.